A second approach recruits a common, typically mild respiratory virus called an adenovirus, makes it unable to replicate and gives it the ability to produce the target norovirus protein.

When we think of climate change, we may consider extreme weather events—record-breaking heat waves, heavy downpours and ...

Lafayette College’s communications division sent out a community-wide email notifying students and faculty of a recent surge ...

In an early clinical trial, an experimental norovirus vaccine given as a pill produced defensive responses exactly where it counts—in the saliva of older people most vulnerable to the explosive ...

The Phase 1 trial is an open label, dose ranging clinical study designed to evaluate Vaxart’s second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs.

An early trial of a norovirus vaccine pill has shown promise at protecting against the notorious “winter vomiting” bug, with researchers saying it could potentially be available for use in a ...

Conference call to begin at 4:30 p.m. ETSOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today ...

A cruise ship docked in Fort Lauderdale's Port Everglades on Friday after an outbreak of norovirus affected more than a hundred passengers, according to the Centers for Disease Control and Prevention.

Cases of adenovirus, former Chinese mystery virus ... The new figures follow the growing presence of horror vomiting bug norovirus, which the UKHSA has found it cementing an already significant ...

The "potential second norovirus wave" is in part driven by the recently emerged GII.17 genotype alongside a different, commonly seen, genotype, GII.4. Experts at the UK Health Security Agency said ...

“As norovirus continues to spread across the ... its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

“As norovirus continues to spread across the ... its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. This press release contains forward-looking ...